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Corticosteroids can reverse severe imatinib-
induced hepatotoxicity
Background. Imatinib can induce severe hepato-
toxicity,in 1-5% of CML patients, many of whom
need permanent imatinib discontinuation. Design
and Results: We report 5 CML patients who devel-
oped grade 3-4 hepatotoxicity after 2-8 months in
imatinib. Different aetiologies of liver damage were
ruled out and toxicity recurred in 2 patients with
further attempts at low dose imatinib. In all
patients prednisone or methylprednisolone at 25-
40 mg/day resolved hepatotoxicity in 3-8 weeks
and allowed imatinib to be resumed at full doses.
Corticosteroid were tapered off in 3-5 months
without hepatotoxicity recurrence. Conclusions.
Corticosteroid may avoid discontinuation for hepa-
totoxicity of the most effective anti-CML therapy. 
Tyrosine- kinase inhibitor imatinib (STI571) has
become the first line therapy for most patients with
chronic myelogenous leukemia (CML)1,2 gastro-intestinal
stromal tumors (GIST)3 and other rare neoplasms (der-
matofibrosarcoma protuberans, myeloproliferative disor-
ders with 5;12 chromosomal translocation, hypere-
osinophilic syndromes) with genetic abnormalities
involving PDGF receptors.4,5 In combination with cyto-
toxic drugs it has acquired an important role in the treat-
ment of BCR/ABL positive acute lymphoblastic leukemia
6, 7 and evidenced some activity in relapsed malignant
gliomas.8 In spite of a generally good tolerance, imatinib
can induce severe hepatotoxicity in 2-5% of treated
patients.1, 9, 10 While generally reversible after imatinib dis-
continuation, this adverse effect often recurs with drug
reintroduction and many patients are prevented from the
use of a very effective drug.1, 9-11, 13
Here we describe 5 CML patients displaying imatinib-
induced hepatotoxicity that completely resolved after the
introduction of corticosteroids for a few months, thus
allowing imatinib resumption and achievement of com-
plete hematological and cytogenetic responses (CCR).
Patients and results
All patients displayed normal values of liver enzymes
and functions at the beginning of imatinib therapy. The
first patient evidenced markers of previous hepatitis B
(HbsAg negative, HBV-DNA negative, anti-HbsAg posi-
tive, anti-HBc positive); no liver disease was found in the
others. All markers of active viral hepatitis were negative
at the time of aminotransferase increment.
Case 1. Fifty year old male with chronic phase CML.
He began imatinib therapy in October 2000 for cytoge-
netic resistance to interferon + cytarabine. Two months
later AST and ALT values increased, in spite of prompt
drug discontinuation, up to 10 × (350 U/l) and 30 × (1080
U/l), respectively, the upper normal limits (UNL).
Bilirubin, ALP, albumin, PT, fibrinogen remained
unchanged, whereas anti-thrombin III dropped to 42% of
the normal level. No HBV reactivation was detected.
Anti-mitochondria and anti-smooth muscle antibodies
were absent. Liver biopsy documented areas of necrosis,
fibrous scars and peri-portal inflammatory infiltrate.
Aminotransferases and anti-thrombin III normalised in 2
months after drug withdrawal; however, 2 further
attempts at low dose imatinib were again followed by
aminotransferase increments. Meanwhile, CML hemato-
logical relapse occurred. In July 2001 imatinib therapy
was further attempted, starting from 300 mg/day, in asso-
ciation to prednisone 25 mg/day for 5 months: hepato-
toxicity did not recur and imatinib dose could be escalat-
ed to 400 mg/day. A CCR was achieved, while pred-
nisone was tapered and discontinued after 5 more
months. The patient is still on imatinib therapy, in CCR,
without hepatotoxicity recurrence. 
Case 2. Sixty-six old woman with chronic phase CML.
She began imatinib treatment (400 mg daily) in
November 2000 for cytogenetic resistance to interferon.
After 8 months of therapy aminotransferase values
increased up to 406 (AST) and 421 (ALT) U/l (13 x UNL),
without evidence of cholostasis or liver failure. Anti-
mitochondria and anti-smooth muscle antibodies were
absent. Imatinib was discontinued, without aminotrans-
ferase improvement for 2 months. Prednisone was then
given at 50 mg/day for 4 weeks (September 2001) with
resolution of hepatotoxicity, then tapered off in 2 more
weeks. A further attempt at lower dose imatinib (200 mg
daily) was again followed by hepatotoxicity, that
regressed after prednisone resumption at 25 mg/ day.
Prednisone at 25 and then 12.5 mg daily for 6 months
allowed imatinib to be reintroduced at 300 mg daily
without hepatotoxicity. CCR was obtained but the
patient died of undifferentiated thyroid cancer in June
2004.
Case 3. Seventy-nine old woman. She started imatinib
(300 mg/day) in April 2002 for CML in chronic phase,
after 6 months in hydroxyurea treatment. In September
2002 imatinib was increased to 400 mg daily but, 4
weeks later, while partial cytogenetic response had been
achieved, AST and ALT levels progressively increased in
spite of drug discontinuation up to 946 and 2243 U/l (31
and 60 × UNL, respectively). Cholostasis markers and
hepatic synthesis were not affected. Anti-mitochondria
and anti-smooth muscle antibodies were absent.
Methylprednisolone was given (40 mg daily) and amino-
transferase values completely subsided in 3 months,
while CML hematological relapse occurred. Imatinib
therapy was then resumed (200 and then 300 mg daily),
together with prednisone 25 mg/ day, without hepato-
toxicity recurrence. Prednisone was tapered (5-10 mg
daily) and then discontinued after 8 months, while ima-
tinib dose was increased to 400 mg daily, with optimal
tolerance and CCR achievement. The patient is still tak-
ing imatinib in continuous CCR.
Case 4. Seventy-eight old male with accelerated phase
CML. He started imatinib treatment at 300-600 mg daily
in May 2001. Six months later, while in hematological
remission, AST and ALT levels increased up to 117 and
183 U/l (4 × and 6 ×, respectively, UNL) and GGT to 150
U/l. Imatinib was temporary stopped and prednisone
given (25 mg daily), to achieve hepatotoxicity resolution.
Imatinib could be resumed 3 weeks later at 300 and then
600 mg daily, while prednisone was reduced to 12.5 mg
daily and maintained at that level because of concomitant
chronic bronchopneumopathy. Cytogenetic response
was not obtained and the patient died of blastic phase in
May 2003.
Case 5. Sixty old woman. Chronic phase CML was
diagnosed in June 2004 and imatinib started at 400 mg
daily. In January 2005, while in CCR, AST and ALT val-
ues increased up to 190 and 360 U/l, (6 × and 10 × UNL,
respectively), without other liver abnormalities. Imatinib
was stopped but one week later aminotransferase values
were unchanged. Prednisone (25 and then 37 mg/day)
was given and hepatotoxicity resolved in 4 weeks. CML
relapse occurred and imatinib has been resumed in March
2005 (300 and then 400 mg/day), while maintaining
prednisone 25 and then 12.5 mg/day until May 2005.
From June 2005 imatinib dose was increased up to 800
mg/day because of acquired CML resistance.
Hepatotoxicicity did not recur but only a partial hemato-
logical response was achieved, due to an acquired
BCR/ABL mutation. A complete hematological and
minor cytogenetic response has been then achieved by
December 2005, after addition of continuous low dose
ARA-C (10 mg/day) to imatinib 800 mg /day without
signs of liver toxicity.
Table1 summarises main clinical data of the 5 patients. 
Discussion
Liver toxicity developed in our patients after 2-8 (medi-
an 6) months of imatinib therapy. Aminotransferase
increase was very pronounced (grade 4 toxicity according
to W.H.O.) in 2 patients, moderate (grade 3) in 3,
although, differently from other reports (11-13), bilirubin
remained in the normal range. Patient 1 probably had the
most severe liver damage, with reduction of AT III and
istological findings of hepatic necrosis, fibrosis and
inflammatory infiltrate. However, re-activation of previ-
ous hepatitis B could be ruled out. 
The role of imatinib in liver damage was evidenced in
patients 1 and 2 by the recurrence of aminotransferase
increment every time the drug was resumed before corti-
costeroid addition and, in all patients, by the absence of
different liver damage aetiologies.
Pathogenic mechanisms of imatinib-induced hepato-
toxicity are unknown; however, istopathology findings
from patient 1 and the response to corticosteroids sug-
gested an inflammatory reaction. Some recent reports of
imatinib-induced toxicity also pointed out similar- hepa-
titis features: aminotransferase increment11-13 and istolog-
ical evidence of focal necrosis and inflammatory infil-
trate. 
While liver damage seems to be reversible after ima-
tinib discontinuation, 2 cases of fatal hepatic failure were
reported: the first was a CML patient taking imatinib and
paracetamol, this suggesting a synergism in drug toxici-
ty14; the last was a patient treated for polycythemia vera.15
In that case, pathological examination revealed different
features: massive necrosis and diffuse microthrombi in
liver, spleen and lung vessels. 
Four of our 5 and 3 of the 5 described patients11, 12, 15
were > 60 year old when hepatotoxicity developed; how-
ever, imatinib hepatotoxicity was not found to be more
frequent in large casistics of old patients.16,17 
In our patients hepatotoxicity promptly regressed after
the addition of prednisone or methyl-prednisolone. This
allowed imatinib prosecution and CCR achievement in 3
chronic phase patients. Moreover, corticosteroids were
discontinued after a few months without hepatotoxicity
recurrence in spite of increased imatinib dosage in 2
patients up to 600 and 800 mg/day, respectively.
Therefore, corticosteroids look as a promising
approach in imatinib- induced hepatotoxicity to avoid the
permanent discontinuation of a very effective anti- neo-
plastic drug.
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Table 1. Patients' main clinical features.
CASE 1 CASE 2 CASE 3 CASE 4 CASE 5
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peak ALT value (U/l) 1080 412 2243 183 360
other liver abnormalities AT III 42% No No GGT 150 U/l No
weeks to normal AST/ALT 7 12 12 3 6
liver toxicity recurrence without steroid ** Yes Yes ND ND ND
liver toxicity recurrence No No No No No
with steroid
*Dose reduced for hematological toxicity before the occurrence of liver toxicity.; °CP: chronic phase; AP: accelerated phase.; ** Hepatotoxicity recurrence at 2nd –3rd
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